guest ::
| Home > Publications database > Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours. > print |
| Home > Publications database > Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours. > print |
| 001 | 126609 | ||
| 005 | 20240228140835.0 | ||
| 024 | 7 | _ | |a 10.1111/nan.12161 |2 doi |
| 024 | 7 | _ | |a pmid:24894640 |2 pmid |
| 024 | 7 | _ | |a 0305-1846 |2 ISSN |
| 024 | 7 | _ | |a 1365-2990 |2 ISSN |
| 024 | 7 | _ | |a altmetric:2437265 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-02637 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Goschzik, Tobias |b 0 |
| 245 | _ | _ | |a Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours. |
| 260 | _ | _ | |a Oxford [u.a.] |c 2015 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1508415027_6846 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Wnt activation in medulloblastomas is associated with good outcome. Upfront testing and risk-adapted stratification of patients will be done in future clinical studies. In a cohort of 186 paediatric medulloblastomas our aim was to identify the optimal methods in standard clinical practice to detect this subgroup.Nuclear accumulation of β-catenin was analysed by immunohistochemistry (IHC). DNA of FFPE tissue was amplified by PCR for single-strand conformation polymorphism analysis and direct sequencing of CTNNB1 exon 3. Copy number of chromosome 6 was analysed by multiplex ligation-dependent probe amplification and molecular inversion profiling.Different automated immunostaining systems showed similar results. Twenty-one of 186 samples had nuclear accumulation in ≥5% of cells, 17 samples showed <5% β-catenin positive nuclei. None of these 17 cases had CTNNB1 mutations, but 18 of 21 cases with ≥5% accumulation did, identifying these 18 cases as Wnt-subgroup medulloblastomas. Fifteen of 18 mutated cases showed monosomy 6, 3 had balanced chromosome 6. On the contrary, none of the CTNNB1 wild-type tumours had monosomy 6.Standard neuropathological evaluation of medulloblastoma samples should include IHC of β-catenin because tumours with high nuclear accumulation of β-catenin most probably belong to the Wnt subgroup of medulloblastomas. Still, IHC alone may be insufficient to detect all Wnt cases. Similarly, chromosome 6 aberrations were not present in all CTNNB1-mutated cases. Therefore, we conclude that sequencing analysis of CTNNB1 exon 3 in combination with β-catenin IHC (possibly as pre-screening method) is a feasible and cost-efficient way for the determination of Wnt medulloblastomas. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a CTNNB1 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a beta Catenin |2 NLM Chemicals |
| 700 | 1 | _ | |a Zur Mühlen, Anja |b 1 |
| 700 | 1 | _ | |a Kristiansen, Glen |b 2 |
| 700 | 1 | _ | |a Haberler, Christine |b 3 |
| 700 | 1 | _ | |a Stefanits, Harald |b 4 |
| 700 | 1 | _ | |a Friedrich, Carsten |b 5 |
| 700 | 1 | _ | |a von Hoff, Katja |b 6 |
| 700 | 1 | _ | |a Rutkowski, Stefan |b 7 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 8 |u dkfz |
| 700 | 1 | _ | |a Pietsch, Torsten |b 9 |
| 773 | _ | _ | |a 10.1111/nan.12161 |g Vol. 41, no. 2, p. 135 - 144 |0 PERI:(DE-600)2008293-9 |n 2 |p 135 - 144 |t Neuropathology & applied neurobiology |v 41 |y 2015 |x 0305-1846 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:126609 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |2 G:(DE-HGF)POF3-300 |v Functional and structural genomics |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROPATH APPL NEURO : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l Pädiatrische Neuroonkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|